Upper respiratory tract infection

Applied sciences
Health sciences
Infectious diseases
Pathogenic bacteria

À propos
Confidentialité
Mentions légales

Graph Chatbot

Publications associées (28)

Highly Potent Host-Specific Small-Molecule Inhibitor of Paramyxovirus and Pneumovirus Replication with High Resistance Barrier

Gerardo Turcatti, Marc Chambon, Damiano Banfi, Jonathan Patrice Vesin

Multiple enveloped RNA viruses of the family Paramyxoviridae and Pneumoviridae, like measles virus (MeV), Nipah virus (NiV), canine distemper virus (CDV), or respiratory syncytial virus (RSV), are of high clinical relevance. Each year a huge number of live ...

AMER SOC MICROBIOLOGY2021

Lung Ultrasonography for Risk Stratification in Patients with Coronavirus Disease 2019 (COVID-19): A Prospective Observational Cohort Study

Mary-Anne Hartley, Jean-Yves Meuwly

Background. Lung ultrasonography (LUS) is a promising pragmatic risk-stratification tool in coronavirus disease 2019 (COVID-19). This study describes and compares LUS characteristics between patients with different clinical outcomes. ...

OXFORD UNIV PRESS INC2021

A high-throughput cell- and virus-free assay shows reduced neutralization of SARS-CoV-2 variants by COVID-19 convalescent plasma

Didier Trono, Priscilla Turelli, Florence Pojer, Charlène Mireille Raymonde Raclot, Valeria Cagno, Jérémy Campos, Céline Pellaton

The detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibodies in the serum of an individual indicates previous infection or vaccination. However, it provides limited insight into the protective nature of this immune resp ...

AMER ASSOC ADVANCEMENT SCIENCE2021

Broad-Spectrum Antiviral Agents Based on Multivalent Inhibitors of Viral Infectivity

Francesco Stellacci

The ongoing pandemic of the coronavirus disease (Covid-19), caused by the spread of the severe acute respiratory syndrome coronavirus 2 (SARS CoV-2), highlights the need for broad-spectrum antiviral drugs. In this Essay, it is argued that such agents alrea ...

WILEY2021

Advances in the development of entry inhibitors for sialic-acid-targeting viruses

Francesco Stellacci, Özgün Kocabiyik, Matteo Gasbarri

Over the past decades, several antiviral drugs have been developed to treat a range of infections. Yet the number of treatable viral infections is still limited, and resistance to current drug regimens is an ever-growing problem. Therefore, additional stra ...

ELSEVIER SCI LTD2021

Systematic screening of viral and human genetic variation identifies antiretroviral resistance and immune escape link

Jacques Fellay, Christian Axel Wandall Thorball

Background: Considering the remaining threat of drug-resistantmutations (DRMs) to antiretroviral treatment (ART) efficacy, we investigated how the selective pressure of human leukocyte antigen (HLA)-restricted cytotoxic T lymphocytes drives certain DRMs' e ...

2021

Use of deoxysphingolipids as anti-toxins and anti-virals

Françoise Gisou van der Goot Grunberg

The present invention relates 1-deoxysphingolipids, as well as pharmaceutically acceptable salts thereof, for use in the prevention and/or treatment of intoxication or viral infections, in particular 1-deoxyceramide or a 1-deoxysphingoid base prodrug there ...

2020

Sulfonated Nanomaterials with Broad-Spectrum Antiviral Activity Extending beyond Heparan Sulfate-Dependent Viruses

Francesco Stellacci, Valeria Cagno, Matteo Gasbarri, Chiara Medaglia

Viral infections are among the main causes of death worldwide, and we lack antivirals for the majority of viruses. Heparin-like sulfated or sulfonated compounds have been known for decades for their ability to prevent infection by heparan sulfate proteogly ...

AMER SOC MICROBIOLOGY2020

Page 2 sur 2